Enasidenib is highly active in previously untreated IDH2 mutant AML: Early results from the Beat AML Master Trial Meeting Abstract

  


Authors: Stein, E. M.; Shoben, A.; Borate, U.; Baer, M. R.; Stock, W.; Patel, P. A.; Kovacsovics, T.; Blum, W.; Vergilio, J. A.; Heerema, N. A.; Rosenberg, L.; Marcus, S.; Stefanos, M.; Chervin, J.; Druker, B. J.; Burd, A.; Byrd, J. C.; Levine, R. L.; Mims, A. S.
Abstract Title: Enasidenib is highly active in previously untreated IDH2 mutant AML: Early results from the Beat AML Master Trial
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454837600341
PROVIDER: wos
DOI: 10.1182/blood-2018-99-118287
Notes: Meeting Abstract: 287 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    342 Stein
  2. Ross Levine
    775 Levine
  3. Jordan Chervin
    6 Chervin
Related MSK Work